Lynn Morris to Infant
This is a "connection" page, showing publications Lynn Morris has written about Infant.
Connection Strength
0,573
-
Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy. Antimicrob Agents Chemother. 2016 Apr; 60(4):2248-56.
Score: 0,085
-
Development of phenotypic HIV-1 drug resistance after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2008 Dec 15; 49(5):538-43.
Score: 0,051
-
HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Nov; 24(11):1449-54.
Score: 0,051
-
Polymorphisms in Nef associated with different clinical outcomes in HIV type 1 subtype C-infected children. AIDS Res Hum Retroviruses. 2007 Feb; 23(2):204-15.
Score: 0,045
-
High specificity of V3 serotyping among human immunodeficiency virus type-1 subtype C infected patients with varying disease status and viral phenotype. J Med Virol. 2006 Oct; 78(10):1262-8.
Score: 0,044
-
Insensitivity of paediatric HIV-1 subtype C viruses to broadly neutralising monoclonal antibodies raised against subtype B. PLoS Med. 2006 Jul; 3(7):e255.
Score: 0,043
-
Genotypic and phenotypic characterization of viral isolates from HIV-1 subtype C-infected children with slow and rapid disease progression. AIDS Res Hum Retroviruses. 2006 May; 22(5):458-65.
Score: 0,043
-
Prevalence of HIV-1 drug resistance amongst newly diagnosed HIV-infected infants age 4-8 weeks, enrolled in three nationally representative PMTCT effectiveness surveys, South Africa: 2010, 2011-12 and 2012-13. BMC Infect Dis. 2019 Sep 16; 19(Suppl 1):787.
Score: 0,027
-
The use of dried blood spot specimens for HIV-1 drug resistance genotyping in young children initiating antiretroviral therapy. J Virol Methods. 2015 Oct; 223:30-2.
Score: 0,020
-
Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients. AIDS Res Hum Retroviruses. 2015 Aug; 31(8):776-82.
Score: 0,020
-
Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis. Lancet Infect Dis. 2015 Jul; 15(7):803-9.
Score: 0,020
-
Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS. 2014 Jul 17; 28(11):1673-8.
Score: 0,019
-
Concordance between allele-specific PCR and ultra-deep pyrosequencing for the detection of HIV-1 non-nucleoside reverse transcriptase inhibitor resistance mutations. J Virol Methods. 2014 Oct; 207:182-7.
Score: 0,019
-
Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial. Lancet Infect Dis. 2012 Jul; 12(7):521-30.
Score: 0,016
-
HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS. 2011 Jul 31; 25(12):1461-9.
Score: 0,015
-
Rapid development of antiretroviral drug resistance mutations in HIV-infected children less than two years of age initiating protease inhibitor-based therapy in South Africa. AIDS Res Hum Retroviruses. 2011 Sep; 27(9):945-56.
Score: 0,015
-
Detection of low-level K65R variants in nucleoside reverse transcriptase inhibitor-naive chronic and acute HIV-1 subtype C infections. J Infect Dis. 2011 Mar 15; 203(6):798-802.
Score: 0,015
-
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA. 2010 Sep 08; 304(10):1082-90.
Score: 0,014
-
Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2007 Feb 01; 44(2):148-53.
Score: 0,011